← Product Code [JHW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JHW) · K122083

# ELITECH CLINICAL SYSTEMS CK NAC SL (K122083)

_Elitechgroup · JHW · Aug 22, 2012 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JHW/K122083

## Device Facts

- **Applicant:** Elitechgroup
- **Product Code:** [JHW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JHW.md)
- **Decision Date:** Aug 22, 2012
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1215
- **Device Class:** Class 2
- **Review Panel:** Clinical Chemistry

## Indications for Use

ELITech Clinical Systems CK NAC SL is intended for the quantitative in vitro determination of creatine kinase (CK) in human serum and plasma on ELITech Clinical Systems Selectra analyzers. It is not intended for use in Point of Care settings. Creatine phosphokinase and its isoenzymes measurements are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.

## Device Story

CK NAC SL is an in vitro diagnostic reagent kit for quantitative measurement of creatine kinase (CK) activity in human serum and plasma. Used on ELITech Clinical Systems Selectra analyzers in clinical laboratory settings by trained personnel. Principle of operation: kinetic UV method; CK catalyzes conversion of creatine phosphate and ADP to creatine and ATP; subsequent enzymatic reactions involving hexokinase and G-6-PDH produce NADPH; increase in NADPH concentration is directly proportional to CK activity. Output is a quantitative measurement of CK activity (U/L). Results assist clinicians in diagnosing and monitoring myocardial infarction and muscle diseases. Device includes calibrator (ELICAL 2) and controls (ELITROL I/II) to ensure accuracy and precision.

## Clinical Evidence

Bench testing only. Precision evaluated per CLSI EP5-A2 (n=80, CV% 0.7-3.9%). Linearity established per CLSI EP6-A (10-1714 U/L). LoD/LoQ determined per CLSI EP17-A (1 U/L and 5 U/L respectively). Interference testing per CLSI EP7-A2 showed no significant interference for bilirubin, triglycerides, acetaminophen, ascorbic acid, or acetylsalicylic acid. Method comparison study (n=100) against Roche CKL yielded y = 1.012x + 2, r=0.998. Matrix comparison (serum vs plasma) yielded r=1.000.

## Technological Characteristics

Reagents: Imidazole buffer, D-Glucose, N-Acetyl-L-Cysteine, Magnesium acetate, NADP, EDTA, Hexokinase, G-6-PDH, sodium azide. Kinetic UV method. Analyzers: Selectra ProM. Calibration: 28-day frequency. Calibrator/Controls: Lyophilized human serum-based. Connectivity: Standalone analyzer system.

## Regulatory Identification

A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

# Decision Summary

Statement for the Record, k122083

This 510(k) was reviewed under OIVD’s Pilot Triage Program. This program represents an internal workload management tool intended to reduce internal FDA review resources for 510(k) applications that are of good quality upon receipt by FDA.

The information in the 510(k) is complete and supports a substantial equivalence (SE) determination. Please refer to the applicant’s 510(k) summary for a summary of the information that supports this SE determination.

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JHW/K122083](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JHW/K122083)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com